Mangrove Partners Cure Vac N.V. Transaction History
Mangrove Partners
- $890 Million
- Q2 2024
Shares
2 transactions
Others Institutions Holding CVAC
# of Institutions
97Shares Held
14.3MCall Options Held
241KPut Options Held
419K-
Israel Englander Millennium Management LLC | New York, Ny2.87MShares$8.27 Million0.0% of portfolio
-
Steven Cohen Point72 Asset Management, L.P. | Stamford, Ct2.42MShares$6.98 Million0.02% of portfolio
-
Black Rock Inc. New York, NY2.25MShares$6.49 Million0.0% of portfolio
-
Bill & Melinda Gates Foundation Seattle, WA1.6MShares$4.6 Million9.09% of portfolio
-
Camber Capital Management LP Boston, MA550KShares$1.58 Million0.05% of portfolio
About CureVac N.V.
- Ticker CVAC
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 187,467,008
- Market Cap $540M
- Description
- CureVac N.V., a clinical-stage biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202, a prophylactic mRNA-based vaccine, which ...